Enzon Pharmaceuticals (OTCMKTS:ENZN), Inc., headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.
The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology. Through strategic partnerships and licensing agreements, Enzon expanded the global reach of its oncology portfolio and supported the development of additional PEGylated molecules targeting cancer and hematologic disorders.
Enzon’s PEGylation platform has been applied to multiple pipeline candidates at various stages of clinical development. Research efforts have included novel conjugates designed to selectively target malignant cells while reducing dosing frequency. By collaborating with academic institutions and other biopharmaceutical companies, Enzon advanced its programs across North America, Europe and Asia.
Over its history, Enzon Pharmaceuticals has maintained a leadership team with expertise in drug development, regulatory affairs and commercial strategy, guiding the company through licensing, clinical trials and lifecycle management of its products. Its pioneering work in PEGylation continues to influence the broader biopharmaceutical industry.
